Ofloxacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ofloxacin: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Ofloxacin is a fluoroquinolone antibiotic historically used to treat bacterial infections. The TxGNN model’s top-ranked prediction suggests possible relevance to Polyclonal Hyperviscosity Syndrome, but this specific candidate currently has 0 clinical trials and 0 publications in direct support, and the mechanistic distance between an antibacterial agent and a plasma-protein disorder is substantial.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (fluoroquinolone-class antibiotic); no TFDA-approved indication text is available — the drug is not currently marketed in Taiwan |
| Predicted New Indication | Polyclonal Hyperviscosity Syndrome |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| India Market Status | Not marketed (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Ofloxacin is part of the fluoroquinolone antibiotic class, its efficacy in treating bacterial infections has been well established, and its predicted association here is derived purely from the TxGNN knowledge-graph model rather than a demonstrated mechanistic pathway.
Polyclonal hyperviscosity syndrome is a hematological/immunological condition driven by excess circulating immunoglobulins or plasma proteins — it is not an infectious disease, and there is no known pharmacological rationale connecting a DNA-gyrase-inhibiting antibiotic to plasma viscosity regulation. The TxGNN score (99.91%) is high in absolute terms, but the disease’s model rank (2015th out of the full candidate list) and complete absence of clinical or literature evidence indicate this is a graph-topology-driven association rather than a mechanistically grounded one.
Notably, other predictions further down this drug’s candidate list — monoclonal gammopathy (rank 6, 20 supporting PubMed articles including a Phase 3 RCT) and septicemic plague (rank 8, 20 supporting PubMed articles including animal-model efficacy studies) — have substantially stronger real-world evidence than the top-ranked candidate reported here. These may warrant separate evaluation as more actionable repurposing leads for Ofloxacin.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
India Market Information
Ofloxacin is not currently marketed in Taiwan (0 registered licenses); no license records are available to summarize.
Safety Considerations
- Drug Interactions: Ofloxacin has 383 total documented interactions (ddinter). Notable Major-level interactions include: Hydrocortisone, Bupropion, Triamcinolone, Dexamethasone, Betamethasone, and Chlorpropamide. Notable Moderate-level interactions include: Acarbose, Famotidine, Albiglutide, Alogliptin, Metformin, Pioglitazone, Loperamide, Acetylsalicylic acid, Balsalazide, Bisacodyl, Calcium Phosphate, Calcium acetate, Canagliflozin, and Potassium citrate.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (polyclonal hyperviscosity syndrome) has no clinical trial or literature support and lacks a plausible mechanistic link to Ofloxacin’s known antibacterial activity — evidence level is L5 (model prediction only). TFDA labeling data (warnings/contraindications) is also a blocking data gap, preventing any safety pre-assessment.
To proceed, the following is needed:
- TFDA package insert / warnings and contraindications (DG001, currently blocking)
- Detailed mechanism of action data (DG002)
- A mechanistic hypothesis linking fluoroquinolone pharmacology to plasma hyperviscosity, or reconsideration of higher-evidence candidates from this drug’s list (e.g., monoclonal gammopathy, septicemic plague)
- If pursued, dedicated literature/trial search specific to “polyclonal hyperviscosity syndrome” beyond the current zero-result queries
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.